A Multicenter Longitudinal Open-Label Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod

Brief description of study

The purpose of this study is to learn about changes in cognition (thinking) that happen while being treated with the medication ozanimod, taken by mouth in the treatment of relapsing remitting multiple sclerosis (RRMS). Ozanimod has been approved by the US Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis


Clinical Study Identifier: s19-01612
ClinicalTrials.gov Identifier: NCT04140305
Principal Investigator: Lana Zhovtis Ryerson.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.